Few FDA approved drugs have a reputation as controversial as Ketamine. This reputation is well earned. Originally developed in the 1960s as a short-acting anesthetic for battlefield use, in recent decades it has become notorious as a date-rape drug (‘Special K’), a club drug (‘Vitamin K’) and for its use in veterinary medicine (‘horse tranquilizer’).
However, I venture to bet that Ketamine is about to be rehabilitated for legitimate human uses. Here is why.
The reason for this belief is a most severe crisis in mental health and our approach to treating mental illness. It is not polite to say this, but given the gravity of the situation it needs to be said: It’s not working out. Not really.
Certainly a strong statement, but this sobering reality is becoming increasingly apparent. Every year, upwards of 10 million people experience a major depressive episode in the US alone. The number of people who never see a professional – and are thus never diagnosed – is likely much higher. Each of these episodes can be expected to last for months to years and is characterized by utter misery; a substantial number is terminal (the number of suicides in the US outnumbers the number of violent non-self gun deaths by about 3:1). Currently available “antidepressants” (a term I would use only in quotation marks, as most struggle to beat placebo except for the most extreme cases and might appear statistically more effective than they actually are) – these days usually a selective serotonin reuptake inhibior (SSRI) – can be expected to help one in ten people, and only after a trial period of 4 weeks to several months. Of course, if the depression happens to coincide with an underlying bipolar tendency, treatment with an SSRI will likely trigger a dysphoric mania. In other words, one will never reach the end of the interval that the SSRI needs to take to work (if it ever does). Instead, one will – at best – need to be hospitalized. So-called “treatment resistant depression” (in reality, depression that didn’t respond to treatment with a few SSRIs or SNRIs as MAO-inhibitors and tricyclics have largely fallen out of favor due to their side effect profile) is either allowed to take its course (with devastating consequences for the individual) or treated with electroshock therapy (ECT). ECT is remarkably effective in addressing this kind of depression, but the “side effects” (more aptly called treatment effects) like deleterious memory loss are a steep price to pay.
This state of affairs is obviously unacceptable. The good news is that it is increasingly being recognized as unacceptable. The National Institute of Mental Health (NIMH) recently announced that it would no longer fund research based on diagnostic criteria as outlined in the DSM. Psychiatric disorders are the only medical conditions that – for historical reasons – are diagnosed entirely based on subjectively reported symptoms. Doing this for any other condition, e.g. cancer or infectious diseases would obviously be absurd. Molecular biology has seen to that. In the 21st century, this simply will no longer do and the NIMH is essentially willing to start over from scratch.
Enter Ketamine. When Ketamine was used as a battlefield anesthetic in Vietnam and the first Gulf war, it was anecdotally noted that wounded soldiers such treated developed far fewer cases of PTSD than soldiers with similar wounds that were treated with other anesthetics. A couple of years ago, systematic studies showed that the vast majority of patients suffering from major depressive disorders made a rapid recovery when given a low, sub-anesthetic dose (most studies show a dose of 0.5 mg/kg to be effective) of Ketamine.
The clinical effectiveness of Ketamine in these scientific reports sounds too good to be true, particularly when compared with anything else on the market. The effects take hold within days (if not hours, compared with weeks to months for SSRIs), they seem to work for most people, there seem to be few discernible side effects (in stark contrast to – for instance – ECT), and it seems to be equally effective in the treatment of bipolar depression (which is notoriously hard to treat).
So what is the catch? Given the crushing disease burden inflicted by major depressive disorders, the question why this treatment is not readily available arises immediately.
The issue does not seem to be primarily medical in nature. Ketamine *is* a dissociate anesthetic, so the immediate effects on the conscious experience are rather extreme. Based on reports from people who have received low sub-anesthetic doses of Ketamine, the Kantian a priori categories of space and time seem to unravel shortly after the injection. They report that it becomes obvious that shared reality is a construct – brought about by the normal operation of the brain – but that Ketamine suspends this normal construction process, allowing for different reconstructions of reality. At higher doses, the reports speak of “leaving flatland” and becoming aware of higher dimensional objects that only appear to be separate when projected onto a low-dimensional space (such as the one we commonly perceive). Whether these experience reports sound scary or intriguing, there is no question that these experiences do not last very long. Given the short half-life of Ketamine and depending on individual metabolism and route of administration (IM or IV), these dissociative effects last for an hour or two, not longer.

One of the most remarkable figures I've ever seen. Dissociative symptoms over time. x-axis is nonlinear. Differences at all time points other than the 40 minute mark are not significant. Adapted from Diazgranados, Nancy, et al. "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression." Archives of general psychiatry 67.8 (2010): 793.
It is also reassuring that the patients could *answer* the CADSS, so they couldn’t have been too far gone. Intriguingly, while there was no significant difference between placebo and ketamine group expect for the 40 minute mark, *all* the mean scores of the placebo group seem to be slightly above the ketamine group. The CADDS features items like: “Do objects look different than you would expect?”. It is not inconceivable that, the experience properly calibrated the scale of the Ketamine group.
Obviously, there are no studies on long term effects in humans at this point, but similar studies on monkeys are encouraging. Animals which had received similar doses for long periods of time on a daily basis show that the dose has to be relatively high and the period of time relatively long to demonstrate impairment. Moreover, the doses involved in the treatment of pain are usually considerably higher, without reports of long term ill effects. To be clear: *Any* potential neurotoxicity is obviously cause for serious concern. However, all medical decisions involve tradeoffs. Depression it itself is increasingly linked to neurotoxicity. Moreover, the spectre of neurotoxicity can lurk where one least expects it, e.g. from antibiotic treatments. In addition, Ketamine seems to potentially *reverse* depression (or stress) induced brain damage via synaptogenesis. The moral of the story is that one should not embark on a course of medical treatment unless the expected upside (far) exceeds the expected downside.
Of course, there is a rub. More than one, actually. The two biggest and uncontested issues seem to be unclear mechanism of action as well as sustainability.
The first issue is that we do not really know or understand how Ketamine seems to bring about its antidepressant magic. Many theories are currently being explored in active research. Some of the hottest trails are NMDA antagonism, neurogenesis and dentritic sprouting. Personally, I believe there might be something to the notion that one is “growing a prefrontal forest”, strengthening prefrontal networks that are in turn able to better quench aberrant activity originating in evolutionary older structures (amygdala, limbic system, etc.) One way or the other, glutamate seems to be involved. While it may sound unsettling that we do not understand the mechanism of a treatment, this situation is far from unique. As a matter of fact, we do not understand the mechanism of action of *any* anesthetic drug. Similarly, there is plenty of evidence that even SSRIS don’t work the way we thought they do. There is mounting empirical support for the notion that the Serotonin action is largely incidental, and that neurogenesis is really behind their therapeutic effects.
The second issue – that of sustainability – is more serious. Curiously, the effects don’t seem to last. While Ketamine can rapidly pull someone out of a serious depression, the depression seems to return in time, requiring a “booster” shot to banish the demons again, even for a short while. The time until relapse is different from individual to individual, ranging from weeks to months, but it is intriguing that there is a time constant at all.
However, there are many chronic diseases that require daily administration of medications, including injections. In this regard, Ketamine isn’t even all that different from most other antidepressants, which are – more often that not – a pretty permanent deal. Many have to keep taking them, for fear of relapse. The real issue why these treatments are not more readily available seems to be economic in nature.
Ketamine is an extremely cheap drug, as it has been off patent for almost 40 years. Put differently, there is no money to be made here. The FDA is tasked with protecting the public from harmful treatments. Thus, the approval process is lengthy and costly. In reality, only a major pharmaceutical company has the financial resources to spearhead the approval of a drug. In the case of Ketamine, this is unlikely to happen, as these companies could never realistically expect to recover their expenses. To be clear, Ketamine already *is* FDA approved, but not for the treatment of depression. There are already some courageous pioneers who will administer Ketamine today (for a king’s ransom) in its off-label use for depression. This is not in itself unusual. Many drugs – once FDA approved – are prescribed for off-label uses. For instance, Modafinil was initially approved for the treatment of narcolepsy. Today, the vast majority of prescriptions are not issued by neurologists for narcoleptics, but rather by primary care physicians for people who feel a little tired – or simply because people want to use it. So in principle, Ketamine already is available for the treatment of depression, off-label. However, the overwhelming majority of psychiatrists is unlikely to touch a drug that is a PCP derivative and needs to be injected, no matter how effective. This problem is not unique to Ketamine. Once a drug has acquired a certain infamy, it is hard to change minds. For instance, Thalidomide is now being explored as an effective cancer treatment, precisely because its such a potent inhibitor of angiogenesis. But that’s a hard sell, given its historical record.
Where does this leave us? In an uncomfortable (as millions are suffering right now), but hopeful position. The evidence for the antidepressant effectiveness of Ketamine (for whatever, yet to be understood reason) is so overwhelming that quite a few pharmaceutical companies are feverishly working on Ketamine analogues and delivery methods (e.g. nasal sprays) that *can* be patented and thus would be worthwhile to put through the highly demanding FDA approval process. Preliminary results are so promising that one can reasonably hope to have truly effective antidepressants available within another decade or so. If this happens, a mental health revolution will be at hand. And it will be sorely needed. Having rapidly acting and unequivocally effective antidepressants widely available and covered by insurance (akin to antibiotics) will make all the difference.
Note: There is no question that Ketamine is a crude drug when it comes to addressing the pathology that underlies depression. Nevertheless, it is a promising and encouraging start, not necessarily the end. Further drug development will need to hone in on the underlying biological target systems (which is why a mental illness classification based on biomarkers is so sorely needed). Moreover, it has not escaped my notice that this discussion has focused on psychopharmacological aspects of depression. There are other aspects that are social, psychological and nutritional in nature, among others. Etiology is likely complex. Breakdown in social coping structures? Sedentary lifestyles? Overfeeding? Intense and chronic stress? Extreme social competition and comparison? Sleep deprivation? Light pollution? Hormone disruption? There certainly is a discussion to be had about these aspects, but not now. It will take a while for research to disentangle these causal links. Meanwhile, it is important to lighten the burden of disease. Thus, the focus was deliberate and we will save a deliberation of other factors for later.
On a final note, it is quite unsettling that virtually all truly effective treatments for mental disorders (e.g. Lithium, ECT, Ketamine, etc.) and psychoactive substances in general (e.g. LSD, Benzos, etc.) were discovered entirely by chance, by pure serendipity. Conversely, all mental health treatments *designed* to do a certain thing, based on our current understanding of the nervous system (e.g. SSRIs, but not just SSRIs – one can always do worse) basically failed to deliver. This suggests that we do not currently understand it very well. Recognizing this should break a lance for pioneering (some call it basic, but there is nothing basic about it) neuroscience research.
PS: This is another installation in an ongoing series on how language really does matter. Most people suffering from depression would reasonably turn to antidepressants, not dissociative anesthetics for help. But just because marketing calls them that doesn’t make it so (whatever one’s position, they are on average so ineffective that a vigorous debate whether or not they are more effective than placebo is even possible. A debate we didn’t see regarding the effectiveness of penicillin. Regardless, there are so many vested interests involved here that the debate is likely to go on. So it is certainly premature to write “Listening to Ketamine” even as people are sick of listening to overhyped BS. Yet, the suffering of the suffering is so severe that I remain hopeful that reason will prevail in the struggle to make depression history. The notion to have effective antidepressants available is a powerful one). As it turns out, the antidepressant effects of some dissociative anesthetics are in all likelihood much more potent than that of current “antidepressants”. Go figure.




















































Bang or BAM? On respecting complex problems
There are simple problems that can be solved with a single bang. The task of understanding the (human) brain is not a simple problem. On the contrary, the classic quote
“The brain, the masterpiece of creation, is almost unknown to us.”
attributed to Nicolaus Steno in 1669 is – by any large – still very much true today. This is owed to the fact that brains – let alone human brains – are essentially unparalleled in terms of their complexity, both in terms of their structure, as well as their function (the activity patterns they are able to produce).
If anything, the past 150 years or so of “modern” research on the brain give us an appreciation for the magnificent scale of the complexity. A single synapse is awe-inspiringly complex. Each single neuron typically has thousands of such synapses (in addition to quite a few other functional parts). Each local circuit contains a plethora of many different varieties of neurons. In the interest of brevity, I will skip a few levels of organization here, but a whole (human) brain contains on the order of 100 billion (or slightly less, but regardless of the precise number about 10 for every single person on the planet or in the neighborhood of the number of stars in the galaxy) neurons (and about an order of magnitude more glia cells, which might play functional roles as well), organized in intricate functional structures, constantly producing dynamic electrochemical activity patterns that in turn change the structure of the synapses and neural connectivity that produced these patterns.
From this concise outline, it should be obvious that understanding the human brain (or any brain for that matter) is not a simple problem.
A great deal has already been written about the Brain Activity Map project (BAM), so I will make this short.
As welcome as the money will be to researchers who have gotten used to funding rate in the single digits in the past decade, it is important to be realistic what 3 billion dollars can buy you.
Depending on the number you use (total program cost, procurement cost, unit cost or flyaway cost), a single Northrop Grumman B-2 spirit bomber costs on the order of 1-2 billion dollars. For the purposes of this argument, I think it not unreasonable to argue that 3 billion will buy you two operational ones. This is a conservative estimate. What matters for the purposes of this calculation is the ultimate cost to the taxpayer which is – if anything – higher.
The US made 21 of them (20 are left, after one of them crashed in Guam in 2008. After originally ordering over 130 at the end of the cold war, but cutting back to 21 after the fall of the Soviet Union). Ever since they became available, they participated in most major campaigns, e.g. pacifying Yugoslavia in the late 1990s.
BANG or BAM? Can we understand the human brain for the cost of these?
As awe-inspiring as these marvels of advanced technology might be, as unparalleled their ability to rain down death and destruction with impunity, they are designed to solve relatively simple (as in tractable and straightforward) problems.
To meaningfully understand structure and function of the human brain, I think that it will take money on the order of magnitude that would buy a fleet of B2 spirits that will blacken the sky. And that is just the funding aspect of it. Money will be necessary, but it won’t necessarily be sufficient. Could the Manhattan project be pulled off without decades of “basic” (there is nothing basic about basic research) research and some fortuitous insights by Einstein himself? Probably not, no matter how much money one threw at the problem. There is a place for a “targeted science” approach in neuroscience, but I will focus on this in another piece.
It is not a bad thing to have challenging goals. It is also not a bad thing to spend money on research (effectively spending money on understanding the world around us). But it is important to be realistic about the magnitude of the challenge and the magnitude of funds devoted to it. There needs to be a balance. If not, money is either wasted, or one sets oneself up for failure, or both.
Human societies can accomplish a great deal if they put their mind to it (in close analogy to reliable computation with unreliable components). We got Buzz Aldrin to the moon and back, safely. But we could not protect him from being ravaged by depression for decades afterwards. Understanding the brain matters, and we do not understand it yet. Our ability to mitigate suffering originating from the human brain is at the very beginning. For instance, it has been suggested that current therapies for clinical depression (most based on manipulating levels of monoamine neurotransmitters) are beneficial for only one in ten patients.
We did build the B2 bomber. We do not yet understand the human brain. I think the latter can be done, but we need to get our priorities straight and have the scale of our challenges match the scale of our resources. This is a political discussion – the US annually spends hundreds of billions of dollars on defense. It is not a foregone conclusion that money spent on keeping world peace is necessarily misspent, but there are many competing policy goals. In times of scarce resources, nothing should be sacrosanct, all options should be on the table.
I’m all for getting serious about understanding the human brain. But in order to do so, we need to actually get serious about understanding the human brain.
What do we want? A bang? A big bang? A BAM? Or rather, a really, really BIG BAM?
If one wants to begin to start understanding the human brain or – with apologies to Churchill – end the beginning of understanding the human brain, one could argue that we need a really big BAM, or more than one.
From what we already learned about the brain, it is clear that the gains in understanding are worth the tremendous cost and effort. However, it is equally clear that it won’t be possible to gain substantial further understanding on the cheap or quickly.
Adequate relative scaling matters. For prospects of success.
Does the brain deserve some respect?
Regardless: How much would an actionable understanding of brain function be worth to you? How much would you be willing to pay, as a personal share?
Update: It now seems that the numbers are in. Way to politicize neuroscience for $100 million. For comparison, people in the US paid 320 times that in overdraft fees in 2012 alone. It is not unreasonable to think in dimensions that scale with the magnitude of the problem, even if the absolute numbers are starting to get a little high. The total projected life-cycle cost for the F35 program is just over 1.5 trillion dollars. The US built over 12,000 B17 bombers to win WW2. They also built a large number of B24s, B25s, B26s and B29s. It is all about how serious one wants to be about addressing an issue. An estimated billion people suffer from some kind of brain disorder right now. To say nothing of the untold billions who will suffer from one in the future. So even a multi-trillion dollar investment might not get a bad return on investment in terms of reduction of suffering if it yields anything tangible. Can we afford it? Can we afford not to do this? Some people wonder how people in the dark ages got by, without the benefit of understanding the source of all their troubles with regard to bacteria and viruses. I wonder if people in the future will ask the same question (mutatis mutandis) about us.
That said, it is undoubtedly true that we are in urgent need of new tools to probe the brain, as our available methods are woefully inadequate for the task. And the new acronym – BRAIN – is also much improved. Hedged excitement as the most suitable way to move ahead?